SAB Biotherapeutics price target lowered to $3 from $7 at Chardan » 07:4108/1108/11/22
Chardan analyst Keay…
Chardan analyst Keay Nakae lowered the firm's price target on SAB Biotherapeutics to $3 from $7 and keeps a Buy rating on the shares. The lower price target reflects the loss of over $50M of previously expected revenue from a DoD grant, a pushout of commercial product launches in keeping with the company's latest projected pipeline timelines and a higher projected future share count to account for future capital raises, Nakae tells investors in a post-Q2 research note.
SAB Biotherapeutics price target lowered to $4 from $8 at Baird » 06:3808/1108/11/22
Baird analyst Colleen…
Baird analyst Colleen Kusy lowered the firm's price target on SAB Biotherapeutics to $4 from $8 and keeps an Outperform rating on the shares. The analyst said while there are limited data catalysts in the near term, she continues to see broad potential for the company's DiversitAb platform. She noted further investment in the COVID program are being discontinued, while other programs continue to advance including programs for influenza, T1D, and immuno-oncology.
|Over a week ago|
SAB Biotherapeutics expects cash to fund requirements for 12 months » 08:1808/1008/10/22
Based on its current…
Based on its current operating plans, SAB expects that its existing business plan, cash and cash equivalents, and anticipated cash flows as of June 30, 2022, will be sufficient to fund its operating expenses and capital expenditure requirements for the twelve months following the date our quarterly report on Form 10-Q was made available for issuance.
SAB Biotherapeutics announces anticipated milestones » 08:1808/1008/10/22
SAB continues to execute…
SAB continues to execute on its strategy to build a proprietary immune and autoimmune disorders pipeline, including respiratory and gastroenterological diseases that disproportionately affect immunocompromised patients. SAB 176, anti-influenza human polyclonal antibodies will move towards advanced Phase II development and SAB 195, anti-C. diff. human polyclonal antibodies will move to pre-IND development and filing. SAB will be hosting a "Virtual 2022 Annual R&D Portfolio Update" on Wednesday, August 17th at 10:30am ET to provide an overview of our exclusive polyclonal immunotherapy platform, DiversitAb, and present our portfolio of planned clinical and preclinical development programs. Executives will showcase SAB's innovative science and how the human body fights disease using polyclonal antibodies in a unique, multi-targeted, and natural way.
SAB Biotherapeutics reports Q2 EPS (11c) vs. (11c) last year » 08:1708/1008/10/22
"We continue to…
"We continue to utilize our capabilities and infrastructure to advance our development pipeline in immunotherapeutics directed at unmet medical needs in influenza and Clostridioides difficile (C. diff.) as well as discovery programs in autoimmune disease and oncology. Furthermore, with the validation of our technology in clinical trials in the last year, we are increasingly confident in the platform as we move forward into new indications," said Eddie Sullivan, Ph.D., Co-founder, President and Chief Executive Officer of SAB Biotherapeutics.
|Over a month ago|
SAB Biotherapeutics appoints Scott Giberson to board of directors » 08:2507/1107/11/22
SAB Biotherapeutics announced the appointment of Rear Admiral, retired, Scott Giberson, a former Assistant U.S. Surgeon General and two-star admiral with the U.S. Public Health Service to SAB's Board of Directors, effective July 7, 2022. Currently, RADM Giberson is the President of AMI Expeditionary Healthcare, a company that provides medical services to international aid organizations, humanitarian concerns, the private sector and government agencies in a wide range of remote and challenging environments.
SAB Biotherapeutics hosts two congressmen for a tour of its facilities » 08:2607/0507/05/22
SAB Biotherapeutics hosted U.S. Congressmen Dusty Johnson and Dean Phillips on Friday, July 1, for a tour of SAB's facilities and to learn about SAB's innovative immunotherapy platform that enables a scalable and reliable production of polyclonal antibodies. During their visit, Congressmen Johnson and Phillips toured SAB's Plasma Production Facility, featuring the company's transchromosomic Bovine which provide SAB's fully human polyclonal antibodies for therapeutics. The Congressmen also met with members of SAB's management team to discuss the company's history in COVID-19 treatment development and SAB's current pipeline in influenza, oncology, and type 1 diabetes.
SAB Biotherapeutics appoints Alexandra Kropotova as CMOT » 08:4706/0606/06/22
SAB Biotherapeutics announced the appointment of Alexandra Kropotova, M.D., as CMO, to play a critical role in progressing SAB's proprietary immune and autoimmune disorders pipeline.. Prior to joining SAB, Dr. Kropotova was the Therapeutic Area Head at Global Specialty R&D at Teva Pharmaceuticals, where she led innovative drug development focused on delivering on a broad portfolio of immunology, respiratory, and immuno-oncology assets spanning from pre-IND to BLA/NDA filing of biologics and complex drug-device combination products.
|Over a quarter ago|
SAB Biotherapeutics price target lowered to $7 from $10 at Chardan » 07:4305/1305/13/22
Chardan analyst Keay…
Chardan analyst Keay Nakae lowered the firm's price target on SAB Biotherapeutics to $7 from $10 and keeps a Buy rating on the shares post the Q1 results. The reduced target reflects a higher projected future share count as modeled future capital raises are expected to be more dilutive due to the decline in share price over the last several months, Nakae tells investors in a research note.
SAB Biotherapeutics price target lowered to $10 from $17 at Chardan » 07:3004/0104/01/22
Chardan analyst Keay…
Chardan analyst Keay Nakae lowered the firm's price target on SAB Biotherapeutics to $10 from $17 and keeps a Buy rating on the shares after the company reported its FY21 financial results and issued an update. Last month, the company announced that the NIH had discontinued enrollment in the ACTIV-2 phase 3 trial assessing SAB-185 for mild-moderate COVID-19 infections and the analyst is removing COVID-19 from estimates.